Condition
Extrapyramidal Syndrome
Total Trials
2
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
3 treatments under study, led by Risperidone And Olanzapine
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Early Phase 1 (1)
Phase 4 (1)
Trial Status
Completed2
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT03430596Early Phase 1CompletedPrimary
a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics
NCT00331825Phase 4Completed
Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Acute Dystonia or Parkinsonism
Showing all 2 trials
Research Network
Common Treatments
- Risperidone And Olanzapine1
- Trihexyphenidyl Hydrochloride1
- Pramipexole1
Active Sponsors
- Department of Health1
- Shanghai Mental Health Center1
- Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan1
Top Investigators
Drug Clinical Trial Office, Shanghai Mental Health Center
Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan
Related Conditions
- Schizophrenia1